These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

565 related items for PubMed ID: 17586559

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
    Koopman K, Le Bastard N, Martin JJ, Nagels G, De Deyn PP, Engelborghs S.
    Neurochem Int; 2009 Sep; 55(4):214-8. PubMed ID: 19524111
    [Abstract] [Full Text] [Related]

  • 3. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.
    Biol Psychiatry; 2004 Nov 01; 56(9):670-6. PubMed ID: 15522251
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age.
    Kester MI, Blankenstein MA, Bouwman FH, van Elk EJ, Scheltens P, van der Flier WM.
    J Alzheimers Dis; 2009 Nov 01; 16(3):601-7. PubMed ID: 19276554
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
    van der Vlies AE, Verwey NA, Bouwman FH, Blankenstein MA, Klein M, Scheltens P, van der Flier WM.
    Neurology; 2009 Mar 24; 72(12):1056-61. PubMed ID: 19307538
    [Abstract] [Full Text] [Related]

  • 8. Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
    Gerhardsson L, Blennow K, Lundh T, Londos E, Minthon L.
    Dement Geriatr Cogn Disord; 2009 Mar 24; 28(1):88-94. PubMed ID: 19672066
    [Abstract] [Full Text] [Related]

  • 9. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia.
    Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H, Van Everbroeck B, Cras P, Martin JJ, Vanmechelen E, De Deyn PP.
    Neurobiol Aging; 2008 Aug 24; 29(8):1143-59. PubMed ID: 17428581
    [Abstract] [Full Text] [Related]

  • 10. Longitudinal stability of CSF biomarkers in Alzheimer's disease.
    Blennow K, Zetterberg H, Minthon L, Lannfelt L, Strid S, Annas P, Basun H, Andreasen N.
    Neurosci Lett; 2007 May 23; 419(1):18-22. PubMed ID: 17482358
    [Abstract] [Full Text] [Related]

  • 11. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T.
    Arch Neurol; 2009 Mar 23; 66(3):382-9. PubMed ID: 19273758
    [Abstract] [Full Text] [Related]

  • 12. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
    Mulder SD, van der Flier WM, Verheijen JH, Mulder C, Scheltens P, Blankenstein MA, Hack CE, Veerhuis R.
    J Alzheimers Dis; 2010 Mar 23; 20(1):253-60. PubMed ID: 20164582
    [Abstract] [Full Text] [Related]

  • 13. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
    Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk EJ, Scheltens P, van der Flier WM.
    Neurology; 2009 Oct 27; 73(17):1353-8. PubMed ID: 19858456
    [Abstract] [Full Text] [Related]

  • 14. Study on the association between SOAT1 polymorphisms, Alzheimer's disease risk and the level of CSF biomarkers.
    Lamsa R, Helisalmi S, Herukka SK, Tapiola T, Pirttila T, Vepsalainen S, Hiltunen M, Soininen H.
    Dement Geriatr Cogn Disord; 2007 Oct 27; 24(2):146-50. PubMed ID: 17622762
    [Abstract] [Full Text] [Related]

  • 15. Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease.
    Skogseth R, Mulugeta E, Jones E, Ballard C, Rongve A, Nore S, Alves G, Aarsland D.
    Dement Geriatr Cogn Disord; 2008 Oct 27; 25(6):559-63. PubMed ID: 18536520
    [Abstract] [Full Text] [Related]

  • 16. Increased total-Tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients.
    de Bont JM, Vanderstichele H, Reddingius RE, Pieters R, van Gool SW.
    Eur J Paediatr Neurol; 2008 Jul 27; 12(4):334-41. PubMed ID: 17951083
    [Abstract] [Full Text] [Related]

  • 17. Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?
    Wallin AK, Hansson O, Blennow K, Londos E, Minthon L.
    Int J Geriatr Psychiatry; 2009 Jun 27; 24(6):638-47. PubMed ID: 19123199
    [Abstract] [Full Text] [Related]

  • 18. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
    Höglund K, Hansson O, Buchhave P, Zetterberg H, Lewczuk P, Londos E, Blennow K, Minthon L, Wiltfang J.
    Neurodegener Dis; 2008 Jun 27; 5(5):268-76. PubMed ID: 18309230
    [Abstract] [Full Text] [Related]

  • 19. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
    Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, Wolf S, Otto M, Reulbach U, Kölsch H, Jessen F, Schröder J, Schönknecht P, Hampel H, Peters O, Weimer E, Perneczky R, Jahn H, Luckhaus C, Lamla U, Supprian T, Maler JM, Wiltfang J.
    Neurobiol Aging; 2008 Jun 27; 29(6):812-8. PubMed ID: 17239996
    [Abstract] [Full Text] [Related]

  • 20. Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEε4 genotype.
    Popp J, Lewczuk P, Frommann I, Kölsch H, Kornhuber J, Maier W, Jessen F.
    J Alzheimers Dis; 2010 Jun 27; 22(2):459-68. PubMed ID: 21084733
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.